GlassScriptPhysician profile
Darien Garcia
NPI 1801486881
$3,300.78
in general payments reported to CMS, 2019-2025
25 companies · $27.69 in 2025
The $27.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $688 · 2023: $1,384 · 2024: $962 · 2025: $27.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $783.52 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $372.16 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $341.16 | 2022-2025 | Repatha, Otezla, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $311.92 | 2021-2024 | |
| Glaxosmithkline, LLC. | $242.49 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $225.08 | 2021-2024 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $143.64 | 2023-2024 | Nexletol |
| Abbvie INC. | $124.26 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $119.38 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $79.27 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.81 | 2023-2024 | |
| Exact Sciences Corporation | $70.82 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $69.76 | 2023-2024 | Xarelto |
| Pfizer INC. | $42.38 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $35.35 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $34.41 | 2022-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $26.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.94 | 2022 | |
| Almatica Pharma LLC | $23.53 | 2023 | Loreev Xr, Gralise |
| Amarin Pharma, INC. | $18.29 | 2022 | |
| Redhill Biopharma INC. | $18.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.40 | 2024 | Quviviq |
| Cardiovascular Systems INC. | $6.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darien Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.